NIH Director's Blog: Drug Development

MAY 21, 2020

Because of these and other factors, many experts think antibody-based therapies may offer one of the best near-term options for developing safe, effective treatments for COVID-19. References : [1] Humoral immune response and prolonged PCR positivity in a cohort of 1343 SARS-CoV 2 patients in the New York City region. In the U.S.

Virus 52

Virus Vaccine Laboratories Small Molecule 52

NIH Director's Blog: Drug Development

MARCH 18, 2021

He uses these fundamental insights to guide the design of vaccines and therapeutics, including promising monoclonal antibodies. Now, Veesler and his lab are turning to another mammal in their search for new leads for the next generation of antiviral treatments, including ones aimed at the coronavirus that causes COVID-19, SARS-CoV-2.

Virus 52

Virus Immune Response Clinical Trials Vaccine 52

Drug Target Review

OCTOBER 4, 2023

Antibody-drug conjugates (ADCs) have been a groundbreaking approach to cancer treatment with their ability to deliver cytotoxic drugs directly to diseased cells while sparing healthy tissues. 10 Proteasome inhibitors Since the approval of Bortezomib in 2003, 11 new proteasome inhibitors have emerged with reduced side effects.

Small Molecule 126

Small Molecule Drugs Immune Response Targeted Protein Degradation 126

Codon

AUGUST 27, 2024

For example, many different filoviruses attack white blood cells and cause similar innate immune responses , which makes it difficult to identify a particular species from only their DNA. In 2003, the DHS launched the BioWatch program after five people died and twenty fell ill from touching envelopes laced with anthrax spores.

DNA 84

DNA Hospitals Laboratories Virus 84